Ignite Creation Date:
2024-05-06 @ 12:29 PM
Last Modification Date:
2024-10-26 @ 1:00 PM
Study NCT ID:
NCT03779035
Status:
UNKNOWN
Last Update Posted:
2018-12-19
First Post:
2018-12-12
Brief Title:
Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Study Overview
Official Title:
Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection
Status:
UNKNOWN
Status Verified Date:
2018-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AdBTC-1
Brief Summary:
This prospective open-Label comparative randomized controlled phase III trial was designed to compare the clinical performance of gemcitabine with capecitabine vs capecitabine alone for patients with biliary tract cancer BTC after curative resection
Detailed Description:
Currently complete surgical resection represents the only potentially curative treatment option for cholangiocarcinoma CCA including intrahepatic hilar and distal CCA and gallbladder carcinoma GBCA Because of high rates of disease recurrence and poor survival rates following surgical resection postoperative treatment have been considered to improve patient survival after resection of BTC The systematic review showed a beneficial impact of adjuvant treatment in BTC particularly in patients with involved lymph nodes or resection margins and distal or hilar CCA However in regard of the paucity of randomized data current guidelines recommend inclusion in clinical trials
Previously the data of the BILCAP trial showed an improvement in median overall survival for capecitabine compared to observation alone for BTC indicating capecitabine as the new standard postoperative treatment after curative resection of BTC
Previous phase II studies for advanced BTC showed superiority of the combination gemcitabine capecitabine regimen vs the capecitabine monotherapy the median OS was 127-14 vs 79 months
Based on these data this AdBTC trial will was designed to compare the clinical performance of gemcitabine with capecitabine vs capecitabine alone for patients with biliary tract cancer BTC after curative resection aiming for superiority of the combination regimen vs the oral monotherapy This will be based on the BILCAP protocol applying the similar dosing assessments and dose modifications
The primary endpoint is DFS and secondary endpoints include recurrence free survival OS safety and tolerability of adjuvant CTx quality of life and patterns of disease recurrence
Previously the data of the BILCAP trial showed an improvement in median overall survival for capecitabine compared to observation alone for BTC indicating capecitabine as the new standard postoperative treatment after curative resection of BTC
Previous phase II studies for advanced BTC showed superiority of the combination gemcitabine capecitabine regimen vs the capecitabine monotherapy the median OS was 127-14 vs 79 months
Based on these data this AdBTC trial will was designed to compare the clinical performance of gemcitabine with capecitabine vs capecitabine alone for patients with biliary tract cancer BTC after curative resection aiming for superiority of the combination regimen vs the oral monotherapy This will be based on the BILCAP protocol applying the similar dosing assessments and dose modifications
The primary endpoint is DFS and secondary endpoints include recurrence free survival OS safety and tolerability of adjuvant CTx quality of life and patterns of disease recurrence
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None